The company plans to build two additional plants of similar scale at the Songdo campus, aiming to establish a total production capacity of 400,000 liters, including its existing plant in Syracuse, U.S. Lotte Biologics targets becoming a top 10 global CDMO by 2030, with a projected annual revenue of 1.5 trillion won ($1 billion).
"Lotte Biologics' greatest strength and competitiveness lie in its professional workforce," said Yoo Hyung-duk, head of the business operations division. He added that the company will enhance productivity at the new campus through personnel exchanges between the Songdo and Syracuse facilities.
The Songdo plant will implement advanced technologies such as the Titer Flex Quad System for high-titer drug production and the N-1 Perfusion system for high-density cell cultivation. Lotte Biologics also plans to establish a Bio Venture Initiative to support and collaborate with biotechnology startups.
